SCHEMBL7095909

SCHEMBL7095909

Nn1c(C(F)(F)F)cc(=O)n(-c2cc([N+](=O)[O-])c(Br)cc2F)c1=O

nearest known ligand 0.41

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.41
PKM P14618 1/20 0.41
MAPK1 P28482 2/20 0.41
ALDH1A1 P00352 2/20 0.32
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8408460 0.86 MAPT (0.41) MAPTPKMMAPK1ALDH1A1
SCHEMBL8128189 0.79 MAPT (0.38) MAPTPKMMAPK1ALDH1A1
SCHEMBL6780468 0.75 HPGD (0.43) MAPTMAPK1ALDH1A1
SCHEMBL7097723 0.75 BCAT1 (0.47) MAPTPKMMAPK1ALDH1A1
SCHEMBL7098719 0.75 RXFP1 (0.37) ALDH1A1
SCHEMBL7670892 0.75 AR (0.31)
SCHEMBL7038526 0.75 ESPL1 (0.35) MAPTPKMALDH1A1CYP3A4
SCHEMBL7015227 0.74 BCAT1 (0.35) MAPTALDH1A1
SCHEMBL7026595 0.74 BCAT1 (0.41) MAPTALDH1A1CYP3A4
SCHEMBL9189042 0.73 BCAT1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030032807-A1 Method for the production of 1-amino -3-aryl -uracils BAYER AKTIENGESELLSCHAFT (DE) 2003-02-13 US disclosed
EP-1257540-A1 METHOD FOR THE PRODUCTION OF 1-AMINO-3-ARYL-URACILS Bayer Aktiengesellschaft (DE) 2002-11-20 EP disclosed
WO-2001058883-A1 METHOD FOR THE PRODUCTION OF 1-AMINO-3-ARYL-URACILS BAYER AKTIENGESELLSCHAFT (DE) 2001-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032807-A1 Method for the production of 1-amino -3-aryl -uracils NQO2, QARS1, NUDT1 MAPT 4832/4885PKM 4657/4885MAPK1 3602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.